XML 120 R53.htm IDEA: XBRL DOCUMENT v3.20.1

Acquisition of Prismic Pharmaceutical (Narrative) (Details)	1 Months Ended	12 Months Ended
	Jun. 28, 2019 CAD ($) Share $ / shares shares	Dec. 31, 2019 CAD ($) shares	Dec. 31, 2018 CAD ($) shares
Disclosure of detailed information about business combination [line items]
Shares issued		$ 11,539,417	$ 47,853,745
Number of warrants issued | shares		67,598	236,148
Prismic Pharmaceuticals Inc. ("Prismic")
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value	$ 20,887,209
Prismic Pharmaceuticals Inc. ("Prismic") | Class B subordinate voting shares
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value	$ 16,431,818
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc (shares) | shares	510,940
Share issue price per share | $ / shares	$ 32.16
Prismic Pharmaceuticals Inc. ("Prismic") | Stock options
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value	$ 2,567,305
Number of instruments or interests issued or issuable | Share	89,898
Prismic Pharmaceuticals Inc. ("Prismic") | Warrants
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value	$ 1,888,086
Number of instruments or interests issued or issuable | Share	67,598

X

- Definition

The increase (decrease) in equity shares resulting from acquisition of net assets.

+ References

No definition available.

+ Details

Name:	huge_IncreaseDecreaseThroughAcquisitionOfNetAssetsShares
Namespace Prefix:	huge_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents number of warrants granted during period.

+ References

No definition available.

+ Details

Name:	huge_NumberOfWarrantsGranted
Namespace Prefix:	huge_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the price per share of shares issued.

+ References

No definition available.

+ Details

Name:	huge_ShareIssuePricePerShare
Namespace Prefix:	huge_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2019-01-01
-Paragraph B64
-Subparagraph f
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_EquityInterestsOfAcquirer
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The increase in equity through the issue of equity instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 106
-Subparagraph d
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_iii&doctype=Standard
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_IssueOfEquity
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2019-01-01
-Paragraph B64
-Subparagraph f
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	huge_LegalEntitiesAxis=huge_PrismicPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=huge_ClassBVotingSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=huge_StockOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=huge_WarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: